Founded Year

1896

Stage

PIPE - II | IPO

Market Cap

232.16B

Stock Price

286.10

Revenue

$0000 

About Roche

Roche operates as a company in pharmaceuticals and diagnostics, with a focus on science related to health outcomes. The company offers medicines and diagnostic tools aimed at preventing, diagnosing, and treating diseases across various medical fields. Roche ensures that treatments are tailored to meet the individual needs of patients. It was founded in 1896 and is based in Basel, Switzerland.

Headquarters Location

Grenzacherstrasse 124

Basel, 4070,

Switzerland

+41-61-688 1111

Loading...

ESPs containing Roche

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effectiv…

Roche named as Leader among 15 other companies, including Becton Dickinson, Exact Sciences, and Caris Life Sciences.

Loading...

Expert Collections containing Roche

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Roche is included in 1 Expert Collection, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

Roche Patents

Roche has filed 954 patents.

The 3 most popular patent topics include:

  • molecular biology
  • biotechnology
  • analytical chemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/25/2020

4/8/2025

Mass spectrometry, Ion source, Molecular biology, Molecular biology techniques, Nanotechnology

Grant

Application Date

8/25/2020

Grant Date

4/8/2025

Title

Related Topics

Mass spectrometry, Ion source, Molecular biology, Molecular biology techniques, Nanotechnology

Status

Grant

Latest Roche News

Trump's Bond Buying Spree Surges Past $82 Million Since August

Nov 16, 2025

Trump's Bond Buying Spree Surges Past $82 Million Since August Follow Trump's Bond Buys Hit $82 Million New disclosures from the U.S. Office of Government Ethics show Trump bought at least $82 million in corporate and municipal bonds between late August and early October, part of more than 175 transactions during that span, reported Reuters. Because the forms list only broad value ranges, the maximum possible total exceeds $337 million. Investments Span Major Banks, Big Tech, Intel The filings show a wide array of purchases, including bonds from Goldman Sachs Group Inc’s  (NYSE: GS ), Morgan Stanley  (NYSE: MS ), JPMorgan Chase & Co. (NYSE: JPM ), Meta Platforms Inc.  (NASDAQ: META ), Home Depot Inc.  (NYSE: HD ), CVS Health Inc. (NYSE: CVS ), Broadcom Inc.  (NASDAQ: AVGO )  and Qualcomm Inc. (NASDAQ: QCOM ). Trump also acquired Intel bonds shortly after the U.S. government, under his direction, took a stake in the chipmaker. A White House official said Trump does not manage his own portfolio, which is overseen by a third-party institution, adding that he continues to file required disclosures. Trump has said his companies are held in a trust run by his children. The documents further show he reported more than $600 million in 2024 income from cryptocurrencies, golf properties, licensing and other ventures, and at least $1.6 billion in assets. Trump Secured Massive Global Investment Deals To Boost US Supply Chains Trump announced a sweeping series of trade and investment deals spanning Europe and Asia, securing what he said would be hundreds of billions of dollars in new U.S. investment. Earlier this month, Trump unveiled a framework with Switzerland and Liechtenstein aimed at erasing the $38.5 billion trade deficit by 2028 after imposing 39% tariffs. Swiss firms, including Roche, Novartis, ABB and Stadler, committed major investments across all 50 states. He later announced a U.S.–Uzbekistan economic dea l, saying Uzbekistan would invest $35 billion over three years and more than $100 billion over a decade, targeting critical minerals, aviation, infrastructure, energy and IT. During his Asia tour, Trump said Japan agreed to expand U.S. investments , including $10 billion from Toyota, and a broader $550 billion commitment under a pending trade deal. He also signed a U.S.–Japan pact on critical minerals and rare earths to bolster supply chains and counter China before heading to South Korea for talks with Chinese President Xi Jinping. Loading...

Roche Frequently Asked Questions (FAQ)

  • When was Roche founded?

    Roche was founded in 1896.

  • Where is Roche's headquarters?

    Roche's headquarters is located at Grenzacherstrasse 124, Basel.

  • What is Roche's latest funding round?

    Roche's latest funding round is PIPE - II.

  • Who are the investors of Roche?

    Investors of Roche include SoftBank, Scale AI, BioMedPartners, AME Cloud Ventures, Roche and 3 more.

  • Who are Roche's competitors?

    Competitors of Roche include PreludeDX, MorphoSys, Viatris, AbbVie, Genentech and 7 more.

Loading...

Compare Roche to Competitors

Novartis Logo
Novartis

Novartis develops and offers a range of medicines aimed at treating serious diseases, providing support for patients and healthcare professionals, and conducting research to discover new therapies. The company also focuses on environmental sustainability and ethical practices in the pharmaceutical industry. It was founded in 1996 and is based in Basel, Switzerland.

Servier Logo
Servier

Servier operates as a pharmaceutical company, engages in the research, development, and production of medications for various diseases, including targeted therapies for cancer, cardiovascular treatments, diabetes, and drugs for immuno-inflammatory and neuropsychiatric conditions. The company also produces generic drugs. It was founded in 1954 and is based in Suresnes, France.

B
Boehringer Ingelheim

Boehringer Ingelheim operates within the pharmaceutical and animal health sectors. The company conducts research and development of products for humans and animals. Boehringer Ingelheim serves the healthcare industry with an emphasis on pharmaceutical products. It was founded in 1885 and is based in Ingelheim am Rhein, Germany.

Bristol-Myers Squibb Logo
Bristol-Myers Squibb

Bristol-Myers Squibb operates as a biopharmaceutical company involved in the discovery, development, and delivery of medicines across various therapeutic areas. The company specializes in treatments for oncology, hematology, immunology, cardiovascular disease, and fibrosis, utilizing translational medicine and data analytics. Bristol-Myers Squibb also engages in health equity initiatives through its foundation to improve health outcomes for populations affected by serious diseases. It was founded in 1887 and is based in Princeton, New Jersey.

T
Teva México

Teva México specializes in the pharmaceutical industry, focusing on the development and manufacturing of generic medications. The company offers a range of generic medicines designed to improve health outcomes for patients. Teva México primarily serves the healthcare sector by providing medication options. It is based in Ciudad de México, Mexico.

P
Pfizer

Pfizer is a biopharmaceutical company involved in the discovery, development, and manufacturing of medications and vaccines aimed at improving health outcomes. The company serves the healthcare sector with its medical solutions. It is based in Jakarta, Indonesia.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.